Changes in cellular signaling proteins in extracts from A549, H460, and U2OS cells treated with cisplatin or docetaxel

Voin Petrovic; Camilla Olaisen; Animesh Sharma; Anala Nepal; Steffen Bugge; Eirik Sundby; Bård Helge Hoff; Geir Slupphaug; Marit Otterlei

doi:10.1016/j.dib.2017.03.023

Changes in cellular signaling proteins in extracts from A549, H460, and U2OS cells treated with cisplatin or docetaxel

Data Brief. 2017 Mar 18:12:18-21. doi: 10.1016/j.dib.2017.03.023. eCollection 2017 Jun.

Authors

Voin Petrovic¹, Camilla Olaisen¹, Animesh Sharma², Anala Nepal¹, Steffen Bugge³, Eirik Sundby⁴, Bård Helge Hoff³, Geir Slupphaug², Marit Otterlei¹

Affiliations

¹ Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
² The Proteomics and Metabolomics Core Facility (PROMEC) at NTNU, Faculty of Medicine, Trondheim, Norway.
³ Department of Chemistry, Faculty of Natural Sciences and Technology, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
⁴ Department of Chemistry and Material Technology, Faculty of Natural Sciences and Technology, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

Abstract

Cell extracts from A549, H460, and U2OS human cancer cell lines treated with cisplatin and docetaxel were analyzed by mass spectrometry (MS) proteomic analysis. The extracts were enriched for cellular signaling proteins using a mix of three different immobilized kinase inhibitors (Purvalanol B, Bisindolylmaleimide X, and (R)-3-(4-((1-Phenylethyl)amino)thieno[2,3-d]pyrimidin-6-yl)benzoic acid (SB6-060-05)) on sepharose bead columns. Raw data is deposited in the PRIDE database [1], project number PXD005286. Data presented () shows changes relative to untreated control for each biological replicate for the three cell lines.